Completed PHASE2 INTERVENTIONAL 3-arm NCT00066092

Pegfilgrastim PBPC Mobilization Study

Randomized, Double-Blind Study of Peripheral Blood Progenitor Cell (PBPC) Mobilization by Pegfilgrastim or Filgrastim for Autologous Transplantation in Subjects With Hodgkin's or Non-Hodgkin's Lymphoma.

Sponsor: Amgen

Conditions Hematology Hodgkin's Lymphoma Lymphoma Non-Hodgkin's Lymphoma Oncology

Interventions filgrastim pegfilgrastim 12 mg pegfilgrastim 6 mg

Updated 5 times since 2017 Last updated: Feb 20, 2008 Started: Apr 30, 2003 Primary completion: Mar 31, 2004 Completion: Oct 31, 2004

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00066092, this PHASE2 trial focuses on Hematology and Hodgkin's Lymphoma and remains completed. Sponsored by Amgen, it has been updated 5 times since 2003, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Apr 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Amgen

Data source: Amgen

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

No location information available.